Key Financial Inc’s MiNK Therapeutics INKT Stock Holding History

Key Financial Inc’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47	Hold	4	–	–	﹤0.01%	1340
2026 Q1	$42	Hold	4	–	–	﹤0.01%	1377
2025 Q4	$45	Hold	4	–	–	﹤0.01%	1424
2025 Q3	$59	Hold	4	–	–	﹤0.01%	1441
2025 Q2	$30	Buy	+4	New	+$30	﹤0.01%	1427
2025 Q1	–	Sell	-4	Closed	-$30	–	1399
2024 Q4	$30	Hold	4	–	–	﹤0.01%	1375
2024 Q3	$32	Hold	4	–	–	﹤0.01%	1345
2024 Q2	$41	Hold	4	–	–	﹤0.01%	1328
2024 Q1	$39	Hold	4	–	–	﹤0.01%	1303
2023 Q4	$46	Hold	4	–	–	﹤0.01%	1307
2023 Q3	$47	Hold	4	–	–	﹤0.01%	1331
2023 Q2	$90	Buy	+4	New	+$80	﹤0.01%	1366

Other funds holding INKT

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Key Financial Inc's INKT Position: Q2 2026 in Review

Key Financial Inc held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 4 shares worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Key Financial Inc first reported a position in INKT in Q2 2023 and has held it in 12 quarters since. The position peaked at $90 in Q2 2023. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

Key Financial Inc held 4 shares of MiNK Therapeutics worth $47 as of Q2 2026.
Key Financial Inc left its MiNK Therapeutics share count unchanged in Q2 2026.
MiNK Therapeutics made up ﹤0.01% of Key Financial Inc's portfolio in Q2 2026, its #1340 holding.
Key Financial Inc first reported a position in MiNK Therapeutics in Q2 2023 and has held it in 12 quarters since.
Key Financial Inc's MiNK Therapeutics position peaked at $90 in Q2 2023.
27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Key Financial Inc's 13F filing for Q2 2026, filed 24 Jul 2026.